Each year, millions of children and adults die and suffer from diseases and disorders that could be prevented by current and future vaccines. JN-International investing to accelerate the development and introduction of appropriate and affordable vaccines in impoverished countries. Starting with a focus on vaccines to prevent Meningococcal meningitis, Stroke, Hepatitis C, Herpes, Tuberculosis -  the largest causes of deaths around the world - the current efforts on JN promise to create for these vaccines for the nations around the world. 

 

Meningococcal Vaccines_____________

 

 

      Meningococcal A.C.Y.W-135 polysaccharide vaccine

Phase 3 trials of Meningococcal meningitis A,CY,W-135 plain polysaccharide ( in 2005) and Diphtheria Toxoid ( in 2007) vaccines trials are successfully completed in West Africa and Patent application filed with USPTO & in 136 PCT countries .

 

Phase III Clinical Trial__________________

               Meningococcal A.C.Y.W-135 Diphtheria Toxoid vaccine

Epidemic meningococcal meningitis is an important public health problem in sub-Saharan Africa. Current control measures rely on reactive immunizations with polysaccharide (PS) vaccines that do not induce herd immunity and are of limited effectiveness in those under 2 years of age.

 

Meningococcal groups A C Y and W-135 DT conjugate vaccines were developed using a genetically detoxified Diphtheria Toxoid as the protein carrier.  Phase 3 trial is successfully completed and approved by Ministry of Health of Côte d'Ivoire in North Ivory Coast using 100 sero-negative male and female volunteers.  Protective Sero-conversion recorded in 98% individuals tested by Institute Pasture Research Institute in Ivory Coast.  

 

Diphtheria Toxoid was chosen for low-cost vaccine production. This childhood vaccine may be introduced in Africa during year 2008 for infant immunization at two, three and four months of age.

 

The vaccine had a tremendous impact on the incidence of the disease, resulting in a more than 90% decrease in the number of deaths and clinical cases, and a 66% decrease in asymptomatic carriage (cf. WHO) in sub-Saharan Africa. 

 

Neisseria meningitides serotype X polysaccharide vaccine 

 

A recent 2007 outbreak of X serotype in Niger and Uganda ( WHO) allowed us to develop vaccine against this pathogen. We isolated the pathogen and typed as X serogroup from spinal fluid of infected people.  Colonization of  Neisseria serotypes also found in mucosal secretions. If allows by regulatory, we may include this serotype vaccine to our quadrivalent to make A,C,Y,W-135 and X polysaccharide vaccine.               

Phase I Clinical Trial__________________

Stroke Vaccine

This first stage of stroke clinical trials is designed to gain basic safety and pharmacologic information. Single or multiple conservative doses of the drug will be administered to volunteers. Analysis of these studies allow JN to assess the drug’s mechanism of action in humans, pharmacology, pharmacokinetics, side effects of various doses, safe dosage range, and the optimal route of administration. Animal model experiments using pigs were successfully proved that the vaccine can can protect and cure the Endothelia-1 induced MCA occlusion in experimental pigs with no side effects or damage to vital organs.  Memory related aspects in  vaccination and treated pigs still under evaluation by "Hippocampal Retrieval of Food-Flavor Memory in Experimental Pigs"., unless and until this parameter is proved to be successful, the project cannot move to human trials.

Animal Trials ________________________

Hepatitis C DNA / Protein Vaccine

 

 The current invention draws scope of newer methodologies in the development of vaccine against Hepatitis C virus genotype-1a and b on the basis of phylogenetic analysis of nucleotide sequences of NS3/NS4a genes of multiple genotypes and subtypes of Flaviviruses. The immunization of r-NS3/NS4a protein or DNA induced humoral and cell mediated protective immune response against Hepatitis C viruses 1a and 1b in mouse models and not sure how it works for human? unless we go for Phase 1 in 2008.

Laboratory Phase____________________

Herpes

 

Tuberculosis

 

HIV vaccine initiative / Receptor research

 

 -   View Filed Patents